Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
The Chemours Company is asking shareholders to elect eleven directors and approve several governance and compensation proposals at its virtual 2026 annual meeting on April 24, 2026. Items include director elections, an advisory vote on executive pay, a new 2026 Equity and Incentive Plan, and auditor ratification.
The proxy highlights Chemours’ Pathway to Thrive strategy, focused on operational excellence, growth in areas like semiconductors and data centers, portfolio simplification, and long-term risk reduction. In 2025, the company delivered $5.8 billion in net sales, $742 million in Adjusted EBITDA and returned $78 million in dividends, while recording a net loss of $386 million largely due to litigation-related charges.
Board oversight features an independent chair, lead independent director, fully independent committees and strong risk, cybersecurity and sustainability governance. Since 2018, Chemours reports a 76% reduction in fluorinated organic chemical process emissions and a 52% cut in Scope 1 and 2 greenhouse gas emissions, supporting its Trusted Chemistry and 2030 responsibility goals.
Chemours senior vice president Kristine M. Wellman reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 25,708 restricted stock units, which are scheduled to vest in three equal annual installments beginning on March 1, 2027. To cover tax obligations from previously vesting RSUs and dividend equivalent units, 3,359 shares were automatically withheld at a price of $18.24 per share, and the disclosure states that no shares were sold in the market. After these changes, she reports direct ownership of 73,750.6057 shares, RSUs, and dividend equivalent units in total.
Chemours executive Gerardo Familiar Calderon reported equity compensation changes involving company common stock. He received a grant of 25,708 shares of common stock at a price of $0.0000 per share as a grant, award, or other acquisition, structured as restricted stock units and related dividend equivalent units.
Separately, 2,635 shares were automatically withheld at $18.24 per share to satisfy tax obligations upon vesting of existing restricted stock units; footnotes state that no shares were sold and the transaction is exempt under Rule 16b-3. The new RSU award is scheduled to vest in three equal annual installments beginning on March 1, 2027, and the reported holdings include directly owned shares, RSUs, and dividend equivalent units.
Chemours Chief Executive Officer Denise Dignam reported equity compensation changes. She received a grant of 169,538 shares of common stock at $0.00 per share, in the form of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations on vesting RSUs and related dividend equivalent units, 22,220 shares were automatically withheld at $18.24 per share; the company notes no shares were sold in the market. Following these transactions, she directly holds 335,313.8721 shares, including RSUs and dividend equivalent units.
Chemours Co reported that officer Michael Robert Foley acquired two grants of common stock in the form of restricted stock units. One award covers 25,013 RSUs that vest in three equal annual installments beginning on March 1, 2027, and another covers 50,027 RSUs scheduled to vest on March 1, 2029. Following these awards, Foley directly holds or is credited with 78,540 Chemours equity units, including directly owned shares, RSUs and related dividend equivalent units.
Chemours officer Joseph T. Martinko reported two stock transactions involving company common shares. On March 2, 2026, he acquired 28,488 shares at $0.00 per share through a grant classified as a grant, award, or other acquisition. On March 1, 2026, 2,789 shares at $18.24 per share were automatically withheld to cover tax obligations tied to vesting restricted stock units and related dividend equivalent units, and the footnote clarifies that no shares were sold on the market. After these transactions, his directly held and unit-based interests total 53,889.1669 shares, including common stock, restricted stock units, and dividend equivalent units. The RSU grant is scheduled to vest in three equal annual installments beginning on March 1, 2027, providing a staged equity-based compensation stream over time.
Chemours Chief Financial Officer Shane Hostetter reported equity compensation and related tax withholding transactions in company common stock. On March 2, he acquired 47,387 shares through a grant or award at a stated price of $0.0000 per share, increasing his directly owned and unit-based holdings to 101,857.1999 shares. A related footnote states this restricted stock unit (RSU) award is scheduled to vest in three equal annual installments beginning on March 1, 2027. On March 1, 3,232 shares at $18.2400 per share were automatically withheld to satisfy tax obligations on vesting RSUs and dividend equivalent units, with the filing clarifying that no shares were sold. Following the tax-withholding disposition, his directly held total was 54,470.1999 shares, which a footnote explains includes directly owned shares, RSUs and dividend equivalent units.
Chemours Co Chief Accounting Officer David Will reported an equity award and a related tax withholding transaction. He received a grant covering 8,337 shares of common stock at no cost, structured as an RSU award scheduled to vest in three equal annual installments beginning on March 1, 2027. In a separate transaction, 699 shares were automatically withheld at $18.24 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the footnote states that no shares were sold in the market. Following these transactions, his directly owned holdings, including RSUs and dividend equivalent units, total 33,083.5415 shares.
Chemours Co senior vice president and general counsel Kristine M. Wellman reported routine equity compensation transactions in company common stock. She acquired 1,781 shares at no cost through performance stock units granted under the Long Term Incentive Plan, which vested after the compensation committee certified performance conditions were met.
To cover related tax obligations on vesting restricted stock units and dividend equivalent units, 675 shares were automatically withheld at a price of $18.41 per share; the footnotes state no shares were sold on the market. After these transactions and an adjustment correcting a prior administrative error, her directly owned, restricted stock unit, and dividend equivalent unit holdings total 51,401.6057 shares.
Chemours Co senior vice president and general counsel Kristine M. Wellman reported routine equity compensation transactions in company common stock. She acquired 1,781 shares at no cost through performance stock units granted under the Long Term Incentive Plan, which vested after the compensation committee certified performance conditions were met.
To cover related tax obligations on vesting restricted stock units and dividend equivalent units, 675 shares were automatically withheld at a price of $18.41 per share; the footnotes state no shares were sold on the market. After these transactions and an adjustment correcting a prior administrative error, her directly owned, restricted stock unit, and dividend equivalent unit holdings total 51,401.6057 shares.